Table 1.
Selected results from the KEGG function categories for differentially expressed hepatic proteins from mice treated with risperidone.
| Predicted Dysregulated Functions with RIS | Up | Down | Associated Proteins | |
|---|---|---|---|---|
| Predicted metabolic effects | Energy production (all ATP-generating pathways combined) | 41 | 62 | BCAT2, CS, AGXT, ABAT, NDUFA8, NDUFB8, NDUFS1, COX6B1, CYB5R3, ALDH7A1, TALDO1, ACAA2, ACLY, PRKCA, PDGFRB, GNAS, PGAM2, ENO3, LRP1, ALR1, AOX3, ADIPOQ, HIBADH, COMT, MTHFD1, ECI2, NUDT7, DGKZ, EPHA2, ITGA3, SLC27A1, BLVRB, SEC22B, SMARCC1, ASGR1, BTD |
| Amino acid production | 32 | 37 | BCAT2, CS, ADIPOQ, LAP3, PGAM2, TALDO1, ENO3, ABAT, ACLY, PCBD2, ALR1, DGKZ, GNMT, AGXT, ALDH7A1, PRKCA, GNAS, FTCD, AMDHD1, ATIC, MTHFD1, EPHA2, PDGFRB, ITGA3, AOX3, COMT, ACAA2, HIBADH, TCN2 | |
| Glycolysis | 36 | 7 | ABAT, ACLY, ALDH7A1, AOX3, COX6B1, CS, EPHA2, GNAS, ITGA3, LAP3, NDUFS1, PDGFRB, PGAM2, PRKCA, TALDO1, ALR1, ENO3, | |
| Lipolysis | 27 | 9 | ABAT, ACAA2, ACLY, ADIPOQ, ALDH7A1, BLVRB, COX6B1, CS, ECI2, GNAS, MECR, PDGFRB, PRKCA, SLC27A1, AOX3, NUDT7 | |
| Lipogenesis | 24 | 2 | ABAT, ACAA2, ADIPOQ, ALDH7A1, ALR1, AOX3, DGKZ, GNAS, MECR, PRKCA, SLC27A1, TCN2, SEC22B | |
| TCA/OxPhos/ETC | 16 | 9 | ADIPOQ, BCAT2, NDUFA8, NDUFB8, PGAM2, ALDH7A1, ALR1, COX6B1, ENO3, NDUFS1 | |
| Nucleic acid synthesis | 7 | 13 | EPHA2, GNAS, ITGA3, PDGFRB, PRKCA, SMARCC1, TCN2, ALR1, AMDHD1, ATIC, FTCD, MTHFD1, NUDT7, TALDO1 | |
| Lysosomal function | 10 | 3 | ADIPOQ, CTSS, GSTA3, HGS, LAMP1, RAB11FIP5, SUMF1, RPN2, SEC22B, VAPA | |
| Mitochondrial biogenesis | 11 | 0 | ADIPOQ, GNAS, PDGFRB, PRKCA, SLC27A1, SMARCC1 | |
| Predicted mitogenic effects | Migration/motility | 55 | 21 | DGKZ, ENAH, EPHA2, GNAS, HSPB1, IL1RAP, ITGA3, MSN, NDUFA8, PDGFRB, PRKCA, ROCK2, ADIPOQ, AFDN, ASGR1, ELAVL1, INPP5D, MYH9, NDUFS1 |
| Cell survival | 49 | 6 | CRYAB, DGKZ, EPHA2, GNAS, GSTA3, HSPB1, IL1RAP, ITGA3, NDUFA8, PDGFRB, PRKCA, RNF31, ADIPOQ, ASGR1, ELAVL1, INPP5D, NDUFS1 | |
| Cell proliferation | 46 | 6 | DGKZ, EPHA2, GNAS, HSPB1, IL1RAP, ITGA3, NDUFA8, NDUFB8, PDGFRB, PRKCA, ADIPOQ, ASGR1, ELAVL1, INPP5D, NDUFS1 | |
| Protein production | 13 | 37 | EIF5, EPHA2, FAU, GNAS, HNRNPC, HSPB1, ITGA3, PDGFRB, PRKCA, TRA2B, AARS, ABAT, AGXT, ALDH7A1, ALR1, AMDHD1, ATIC, CRYAB, DDOST, EIF5B, FTCD, GANAB, HGS, HYOU1, NOP56, PABPC1, PUF60, RAB11FIP5, REX02, RPN2, RPS3A1, SEC22B, SNRPB, SNRPG, TALDO1, TARS | |
| Cancer | 25 | 7 | DGKZ, GNAS, GSTA3, ITGA3, KLK3, PDGFRB, PRKCA, ROCK2, EPHA2, HPGD, SMARCC1 | |
| Predicted tissue-damaging effects | Oxidation/ROS generation | 34 | 10 | ABAT, AGXT, ALDH7A1, ALR1, AOX3, BLVRB, COMT, COX6B1, DDOST, EPHA2, GANAB, GNAS, HGS, YOU1, ITGA3, NDUFA8, NDUFB8, PDGFRB, PRKCA, RAB11FIP5, ROCK2, RPN2, ADIPOQ, COX6B1, GSTA3, LAP3, NDUFS1, SMARCC1, |
| Disrupted elimination of toxins/xenobiotics | 8 | 7 | GSTA3, LAP3, ALR1, AOX3, COX6B1, NUDT7, TALDO1 | |
| Protein misfolding | 9 | 1 | DDOST, GANAB, LAP3, RPN2, VCP |